Exact sciences corporation stock.

Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working to develop additional tests, with the goal ofExact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77.Jul 10, 2023 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ... Nov 30, 2023 · The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm ...

Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...

Their dream is closer to reality thanks in part to a $2.15 billion acquisition of their company, Thrive Earlier Detection Corp., one year ago by Exact Sciences Corp., a global leader in cancer-detection testing. “The acquisition of Thrive is a giant leap toward ensuring blood-based, multicancer screening becomes a reality and, eventually, the ...

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... Whirlpool makes Maytag appliances as of 2015. In 2005, the Whirlpool Corporation bought out Maytag for more than $2.7 million in cash, debt and stock. Whirlpool is the nation’s biggest appliance manufacturer.Shares of Exact Sciences Corporation ( EXAS -0.26%) were down 11.3% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare company's ...

About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... "Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that …Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See …Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ...

Oct 20, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ... May 15, 2023 · On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ... Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...Nov 17, 2023 · Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq.

27-Oct-2020 ... ... stock consideration of up to $2.15 billion. The transaction was ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.Nov 1, 2023 · Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent. 02-Aug-2022 ... MADISON, Wis., Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...

10-Jan-2023 ... The most important factor in Exact Sciences' business outlook is its commitment to developing innovative new technologies that improve cancer ...

MADISON, Wis., February 7, 2023 – Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States. OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test …

MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, ...Apr 19, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, Exact ... Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue for Q3 2023, reaching $628 million. The company delivered over a million test results, including a record for Cologuard ...Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... Stock Information · Financial Information · SEC Filings · Quarterly Results · Analyst Coverage ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...Get the latest news and real-time alerts from Exact Sciences Corporation (EXAS) stock at Seeking Alpha. ... EXAS Exact Sciences Corporation. Latest News. Follow $65.82-0.17 (-0.26%) ...Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PM08-Jan-2023 ... 8, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that ...

03-Nov-2023 ... everyone excited? Whoo. The stock is up. That's good. ... Exact Sciences and chairman and CEO Kevin Conroy. ... sciences commitment to earlier ...02-Nov-2023 ... On today's stock market, EXAS stock sank 1.7% to 62.46. Is EXAS Stock Nearing Profitability? Overall, Exact Sciences posted no earnings on ...Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...Instagram:https://instagram. oakmarkfunds5 yr treasury rateeqqqbest site to day trade Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Analyst Forecast. According to 17 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $92.07, which is an increase ... singapore alineshealth insurance companies in las vegas MADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ... orchid island capital Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.22-Feb-2022 ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...